Regeneron Pharmaceuticals (REGN)
NASDAQ • Healthcare
April 2, 2026 at 20:00 UTC
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals is a biotechnology company that discovers and develops medicines built on antibody and genetic insights. Its labs translate biology into candidates, clinical teams test those candidates with rigorous endpoints, and manufacturing scales successful therapies for reliable supply. The operating model favors platforms that can be reapplied across conditions, which speeds learning without cutting corners. Medical affairs focuses on clear labeling and appropriate use, and post-approval work tracks outcomes so guidance can improve. Collaborations with research centers and peers widen the scientific base while keeping control of quality and data. Within healthcare, Regeneron’s role is to move promising science into practical treatment that fits the routines of real clinics.
Analyst Ratings
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings Calendar
Technical Indicators
Regeneron Pharmaceuticals's Technical Indicators Summary
Regeneron shows a bullish leaning driven by price holding above most moving averages including the 200‑day, and momentum measures such as a positive short-term momentum reading support that stance even though MACD and RSI are near neutral. On‑balance volume is constructive and volatility is moderate; however, the pivot level sits above the current price and ADX indicates only a weak trend. Technical takeaway: modestly bullish overall with broad moving‑average support and momentum backing, tempered by limited trend strength.
| Indicator | Value |
|---|---|
ATR (14) | $20.89 (2.74%) |
Bollinger Bands | $724.85 - $784.56 |
RSI (14) | 50.93 |
Stochastic %K (14, 3, 3) | 84.26 |
CCI (20) | 24.74 |
WPR (14) | -36.30 |
Momentum (10) | 24.40 |
MFI | 48.52 |
MACD Level (12, 26) | -1.82 |
ADX (14) | 12.70 |
OBV | 2,367,500 |
Classic Pivot Point | $776.14 |
Fibonacci Pivot Point | $776.14 |
Simple Moving Averages | $662.72 - $765.50(5 indicators) |
Exponential Moving Averages | $672.42 - $758.20(5 indicators) |
Get premium market insights delivered directly to your inbox.
Today's Snapshot
Into the bell, a small sector dip of -0.62% left a soft macro backdrop for REGN. End-of-day figures show busy trading in REGN, with 1.46× typical volume crossing the tape. REGN move sentence: REGN moves on betting its earnings could beat again, with Dupixent Japan approval adding to upside amid soft macro/back.
Price Change
from $756.36 close
+$5.57
Trading Volume
Above avg 683.9K
1M
vs S&P 500 Today
Strong Underperformance
-15.51%
52-Week Position
Upper range
82.8%
Updated: April 3, 2026 at 20:02 UTC
Quote Summary
REGN Headlines
Biotech ETFs Flash Classic Reversal Signal
April 1, 2026
Japan clears Dupixent for bullous pemphigoid
March 24, 2026
Goldman’s Top Healthcare Picks Gain Fresh Catalysts
March 15, 2026
Institutions Boost Stakes in Regeneron
March 15, 2026